The Inflation Reduction Act includes an exemption for orphan drugs for a single indication, but experts say this is far from ...

Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with ...

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited ...

The blood cancer multiple myeloma is deadly. This disease is personal for us because one of our best friends and colleagues died from the complications of this malignancy in 2006.

The market worth was recorded at $3.16 billion in 2024 and is projected to escalate to $3.68 billion in 2025, unfolding at a robust compound annual growth rate CAGR of 16.1%. The proficient growth in ...

Diagonal Therapeutics Inc.’s DIAG-723 has been awarded orphan drug designation by the FDA for the treatment of hereditary hemorrhagic telangiectasia (HHT). Additionally, the EMA has provided a ...

Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out ...

Telomir-1 improved cell survival, reduced oxidative stress, and restored mitochondrial balance in preclinical progeria study.

Senate Republicans released their version of the Trump administration’s “One Big Beautiful Bill Act” on Monday with a few ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorder BRAVE study will explore the ...

Shares of Cero Therapeutics Holdings drew increased retail investor chatter on Tuesday after the company said that the FDA ...